



Attorney Docket Number XMP 2037
Serial Number 09/754,347

#6
J.P.

PATENT

IN THE UNITED STATE PATENT AND TRADEMARK OFFICE

In re application of: Gelber, Daniel et al.
For: COMPOSITION AND METHOD FOR
TREATING THE EFFECTS OF
DISEASES AND MALADIES
Serial No. 09/754,347
Filed January 5, 2001
Art Unit 1651
Examiner Jean Witz
Attorney Docket No. XMP 2037

RECEIVED

SEP 16 2002

TECH CENTER 1600/2900

RESPONSE TO ELECTION OF SPECIES REQUIREMENT

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Responsive to the Examiner's Office Action dated August 13, 2002 requiring an election of species, the applicants, through their representatives, provisionally elect the combination of an antihistamine pharmaceutical (A) and an anti-inflammatory (I) as a nutraceutical. (This election is without traverse).

The examiner further requires election of a specific anti-inflammatory. The applicant provisionally elects stinging nettle and extracts thereof.

Since some of the claims under consideration include additional ingredients, the examiner further required election of a specific immune boosting nutraceutical and a specific anti-oxidant. The applicant provisionally elects zinc and effective salts thereof as an immune booster and ascorbic acid and effective salts thereof as anti-oxidants.

The combination of an antihistamine pharmaceutical (A) and an anti-inflammatory (I) as a nutraceutical is covered by Claims 1-6, 8, 14, 16, 30, 31, 50- 59, 61, 67, 69, 83, 84, and 104-106. Of these claims, Claims 1-6 and 54-59 are generic.

The following claims cover the combination of an antihistamine, an immune-boosting nutraceutical, and an anti-inflammatory: 14, 16, 67, and 69. The following claims cover the combination of an antihistamine, an anti-oxidant nutraceutical, and an anti-inflammatory: 30, 31, 83, and 84. Because the applicant has already elected a specific immune boosting nutraceutical and a specific anti-oxidant, as required by the examiner, it is requested that Claims 14, 16, 30, 31, 67, 69, 83, and 84 be included in the elected group.

In the alternative, should the examiner not find this argument convincing, the applicant, through his representatives, elects the combination of an antihistamine pharmaceutical (A) and an anti-inflammatory (I) as a nutraceutical, covered by Claims 1-6, 8, 50- 59, 61, and 104-106.

Please note that the examiner included Claims 50-53 and 104-106 as covering A+I. Claims 8 and 61 have been added to this list on the grounds that they cover the combination of a pharmaceutical and a generic nutraceutical. The examiner asserted that Claims 4-5 and 57-58 cover species A+B and A+O, but not species A+I; however, as these claims do not exclude the presence of an anti-inflammatory agent, it is the applicant's contention that they should be treated as generic claims.

Respectfully submitted,



Thomas A. Powers
Reg. No. 38,582

Dated: September 12, 2002

KRAMER & ASSOCIATES, P.C.
Crystal Plaza One
2001 Jefferson Davis Highway, Suite 1101
Arlington, Virginia 22202
Telephone: (703) 413-5000
Facsimile: (703) 413-5048

TWK:AMA:nsa



PTO/SB/21 (12-97)

Approval for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/754,347	
Filing Date	January 5, 2001	
First Named Inventor	Daniel Gelber	
Group Art Unit	1651	
Examiner Name	Jean Witz	
Total Number of Pages in This Submission	3	
	Attorney Docket Number	XMP 2037

RECEIVED
SEP 16 2002
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

Fee Transmittal Form	Assignment Papers (for an Application)	After Allowance Communication to Group
Fee Attached	Drawing(s)	Appeal Communications to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Response	Licensing-related Papers	Appeal Communications to Group (Appeal Notice, Brief, Reply Brief)
After Final	Petition Routing Slip (PTO/SB/69) and Accompanying Petition	Proprietary Information
Affidavits/declaration(s)	To Convert a Provisional Application	Status Letter
Extension of Time Request	Power of Attorney, Revocation Change of Correspondence Address	Additional Enclosure(s) (please identify below):
Express Abandonment Request	Terminal Disclaimer	
Information Disclosure Statement	Small Entity Statement	
Certified Copy of Priority Document(s)	Request of Refund	
Response to Missing Parts/Incomplete Application	Remarks	
Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name
Thomas A. Powers, Reg. No. 38,582

Signature

Date September 12, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: _____

Typed or printed name

Signature

Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.